Nyxoah SA Ordinary Shares NYXH 深 滬
已收盤 12-24 16:00:00 美东时间
4.65
-0.010
-0.21%
華盛通- 最 高4.735
- 今 開4.68
- 成交量 3024股
- 最 低 4.645
- 昨 收 4.66
- 總市值 1.75亿
- 52周最高 11.87
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 4.345
- 委 比 -81.82%
- 總股本 3754.48万
- 歷史最高 37.00
- 量 比 0.12
- 振 幅 1.93%
- 歷史最低 4.00
- 每 手 1
- 風險率 1.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Piper Sandler Reiterates Overweight on Nyxoah, Lowers Price Target to $9
Piper Sandler analyst Adam Maeder reiterates Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $12 to $9.
11-15 00:15
Nyxoah Commences Financing Commitment Of Up To $77M
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA) through
11-14 05:45
Nyxoah Q3 EPS $(0.74) Misses $(0.61) Estimate, Sales $2.306M Beat $1.950M Estimate
Nyxoah (NASDAQ:NYXH) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.61) by 21.31 percent. This is a 34.55 percent decrease over losses of $(0.55) per share from the same
11-14 05:15
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
Inspire Medical cut at Jefferies on GLP-1 uptake, potential rivalry
Shares of Inspire Medical Systems (NYSE:INSP) slipped on Friday after Jefferies downgraded the MedTech player to Hold from Buy, citing multiple headwinds for the company, including potential competiti...
10-25 00:39
First US Patients Implanted With Nyxoah's CE-Marked Genio System Signal Strong Demand For Breakthrough Sleep Apnea Therapy
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio SystemEarly Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorizations, and Widespread Payor Coverage
10-06 13:59
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System
Nyxoah announced the first U.S. commercial patients implanted with its Genio® system following FDA approval, marking a significant milestone in treating Obstructive Sleep Apnea (OSA). CEO Olivier Taelman highlighted strong physician demand, successful pre-authorization, and widespread payer coverage. Dr. Andrew T. Huang, the first surgeon to implant Genio commercially in the U.S., praised the system's effectiveness and ease of use. Nyxoah is trac...
10-06 05:00
Nyxoah Enters Underwriting Agreement for Public Offering
The latest announcement is out from Nyxoah ( ($NYXH) ). On September 18, 2025, ...
09-24 04:58
Nyxoah Announces Continued Expansion Of Commercial Footprint In Middle East, Following First Genio Implant In Abu Dhabi In September 2025
Nyxoah Provides an Update on Expanded Middle East PresenceNew Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region Earlier in 2025Mont-Saint-Guibert, Belgium – September 23, 2025,
09-24 04:12
